(Reuters) – A top executive at Baxalta Inc , which was approached with a takeover offer from Shire PLC, said on Wednesday the company did not plan to rush into doing a defensive deal to try to fend off its unwanted suitor.
Chief Financial Officer Bob Hombach said during a presentation webcast from the Morgan Stanley Global Healthcare conference that the company was still interested in doing deals that made sense, but that it would not change its strategy “just because somebody knocked on our door on day 1.”
Shire approached Baxalta shortly after it was spun off from Baxter International into a standalone public company. Baxalta has so far rejected the offer.
Baxalta shares closed up 1 cent at $37.07 on the New York Stock Exchange. (Reporting by Caroline Humer; Editing by Meredith Mazzilli)
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.
